Fig. 6: Overview of therapeutic actionability revealed by ctDNA profiling.
From: Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients
a Frequencies of clinical actionability across different cancer types, broken down by evidence levels. GIST gastrointestinal stromal tumor, HCC hepatocellular carcinoma, NSCLC non-small cell lung cancer, SCLC small cell lung cancer, UGI upper gastrointestinal cancer. b Frequencies of actionable alterations across cancer types. Alterations are grouped by pathway. The right box chart indicates the clonality distribution of different actionable alterations. Centre line, median; box limits, upper and lower quartiles; whiskers, 1.5× interquartile range; points, outliers. c Clonality distribution of actionable alterations in different cancer types. Centre line, median; box limits, upper and lower quartiles; whiskers, data range.
